Filing Flows › Comparisons › DCOY vs SXTP
Decoy Therapeutics vs 60 Degrees Pharmaceuticals: DCOY and SXTP compared
Decoy Therapeutics is the larger company: $228K of revenue in its latest quarter (Q2 2026) against $208K for 60 Degrees Pharmaceuticals (Q2 2026).
Where the money goes: DCOY and SXTP
Decoy Therapeutics (DCOY) · Q2 2026
Decoy Therapeutics, Q2 2026: revenue $228K, net loss $2.4M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
60 Degrees Pharmaceuticals (SXTP) · Q2 2026
60 Degrees Pharmaceuticals, Q2 2026: revenue $208K (+106% year over year), net loss $2.3M, operating cash flow −$2.2M. The chart follows the revenue to costs, profit and cash.
| Decoy Therapeutics (DCOY) | 60 Degrees Pharmaceuticals (SXTP) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $228K | $208K |
| Revenue growth, Y/Y | — | +106% |
| Operating margin | n/m | n/m |
| Net earnings | −$2.4M | −$2.3M |
| Operating cash flow | −$2.7M | −$2.2M |
Questions
Which is bigger, Decoy Therapeutics or 60 Degrees Pharmaceuticals?
Decoy Therapeutics is the larger company: $228K of revenue in its latest quarter (Q2 2026) against $208K for 60 Degrees Pharmaceuticals (Q2 2026).
More: Decoy Therapeutics earnings · how Decoy Therapeutics makes money · 60 Degrees Pharmaceuticals earnings · how 60 Degrees Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.